drugset / Trial / NCT02077361

Summary

A project has been developed in Edmonton, Alberta, Canada to enable male patients with choroideremia to access a clinical trial that replaces the defective gene with a normal copy. This experiment is designed to show that the transfer of a normal copy of the gene to the eye is not only safe but may improve the sight of patients. Only Canadian subjects who meet criteria will be recruited.

Timeline

Start
2015-04
Primary completion
2017-08-30
Completion
2022-05-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rAAV2.REP1 Gene therapy (AAV / viral vector) 0.1 ml Other

Indications